Cargando…
An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Background Metabolic abnormal conditions, such as diabetes and high triglycerides (TGs), are commonly associated with nonalcoholic fatty liver disease (NAFLD). Currently, there is no approved pharmacotherapy for NAFLD. Saroglitazar, the world’s first approved dual peroxisome proliferator-activated r...
Autor principal: | Mitra, Asis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413319/ https://www.ncbi.nlm.nih.gov/pubmed/32782883 http://dx.doi.org/10.7759/cureus.9065 |
Ejemplares similares
-
Effect of Dapagliflozin on Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Single-Center Survey
por: Das, Chandan, et al.
Publicado: (2021) -
Nonalcoholic Fatty Liver Disease and Hypothyroidism: What You Need to Know
por: Bikeyeva, Viktoriya, et al.
Publicado: (2022) -
The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review
por: Ndakotsu, Andrew, et al.
Publicado: (2022) -
Prevalence of Nonalcoholic Fatty Liver Disease at a Tertiary Care Center in Saudi Arabia
por: Hussein, Ghada, et al.
Publicado: (2023) -
Effective Treatment of Nonalcoholic Fatty Liver Disease Using a Community-Based Weight Management Program
por: Hawa, Fadi, et al.
Publicado: (2021)